Next-generation probiotics: a promising approach towards designing personalized medicine
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Second brain, forgotten organ, individual's identity card, and host's fingerprint are the few collective terms that are often used to describe the gut microbiome because of its variability, accountability, and its role in deciding the host's health. Also, the understanding of this host health-gut microbiota relationship can create an opportunity to control an individual's health by manipulating the gut microbiota composition. Several approaches like administration of probiotic, prebiotics, synbiotics, faecal microbiota transplantation have been tried to mitigate the dysbiosis originated ill effects. But the effects of these approaches are highly generic and non-specific. This creates the necessity to design personalized medicine that focuses on treatment of specific disease considering the individual specific gut microbiome. The health promoting commensals could be the new promising prophylactic and therapeutic agents for designing personalized medicine. These commensals are designated as next-generation probiotics (NGPs) and their unusual characteristics, unknown identity and special growth requirements have presented difficulties for researcher, industrial exploitation, and regulatory agencies. In this perspective, this review discusses the concept of NGPs, NGP candidates as tool for designing personalized medicine, designer probiotics as NGPs, required regulatory framework, and propose a road map to develop the NGP based product.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
null (2016) · Philosophy Study · doi:10.17265/2159-5313/2016.09.003 · Cited by 28,317
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“…blockade (ICB) therapy used for tumour amelioration which is evident from the increased CD8þ T-cell infiltration within the tumour environment in addition to the enhanced frequency of effector CD4þ and CD8þ T-cells in the periphery (Chaput et al. 2017; Gopalakrishnan et al. 2018; Park et al. 2018).”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 3×
“The increased efficacy was attributed to the activation of DCs, leading to enhanced CD8þ T-cell priming and accumulation within the tumour microenvironment (Sivan et al. 2015).”
BackgroundInfluentialRinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019) · Microorganisms · doi:10.3390/microorganisms7010014 · Cited by 3,462 · cited 1×
“Rinninella et al. (2019) reviewed that every individual has unique gut microbiota composition which varies throughout the life-span.”
BackgroundHuman Genetics Shape the Gut Microbiome
Goodrich, J. K., Waters, J. L., Poole, A. C., Sutter, J. L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J. T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.053 · Cited by 3,164 · cited 1×
“Another study suggested the probiotic effects of Christensenella minuta against obesity and associated metabolic disorders as they observed alteration of obesity-associated microbial patterns in recipient mice (Goodrich et al. 2014).”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Human gut microbes impact host serum metabolome and insulin sensitivity
Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A. H., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., et al. (2016) · Nature · doi:10.1038/nature18646 · Cited by 2,116 · cited 2×
“vulgatus showed anti-diabetic effect in mice model (Pedersen et al. 2016).”
BackgroundChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Cited by
Intestinal Barrier in Human Health and Disease
Di Tommaso, N., Gasbarrini, A., & Ponziani, F. R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312836 · Cited by 533
Donald, K., & Finlay, B. B. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00874-w · Cited by 354
Next generation probiotics for human health: An emerging perspective
Jan, T., Negi, R., Sharma, B., Kumar, S., Singh, S., Rai, A. K., Shreaz, S., Rustagi, S., Chaudhary, N., Kaur, T., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35980 · Cited by 95
“During infancy, the composition of the gut microbiota is relatively clear and includes a notable number of microorganisms such as Veillonella , Clostridium botulinum , C . coccoides , Bacteroides , and Akkermansia muciniphila [20].”
BackgroundGut microbiota drives structural variation of exogenous probiotics to enhance colonization
Jiang, S., Huang, S., Zhang, Z., Ma, W., Han, Z., Song, Y., Huo, D., Cui, W., & Zhang, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2503371 · Cited by 15
“Numerous studies have explored strategies for enhancing individualized probiotic treatment, 13,14 including optimizing the type of probiotic bacteria, administration timing, and frequency, dietary, encapsulation technologies, and engineered therapies.”
Lu, W., Zha, B., Lyu, J., LingHu, C., Chen, J., Deng, S., Zhang, X., Li, L., & Wang, G. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1500886 · Cited by 4
Metadata
- Authors
- Singh, T. P., & Natraj, B. H.
- Venue
- Critical Reviews in Microbiology
- Publisher
- Informa UK Limited
- Published
- 2021-04-06
- Volume
- 47
- Issue
- 4
- Pages
- 479-498
- ISSN
- 1040-841X (ISSN-L)
- 1549-7828
- OpenAlex
- W3146686135
- Cited by
- 138
- References
- 31
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Next-generation probiotics: a promising approach towards designing personalized medicine. https://app.cochat.ai/papers/10.1080/1040841x.2021.1902940
- The paper
- Singh, T. P., & Natraj, B. H. (2021). Next-generation probiotics: a promising approach towards designing personalized medicine. Critical Reviews in Microbiology. https://doi.org/10.1080/1040841x.2021.1902940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.